QuidelOrtho Corporation (Nasdaq: QDEL) reported an 11.6% third-quarter revenue decline as China and respiratory sales weakened, and Levi & Korsinsky said Nov. 16 it was investigating possible securities-law violations involving the U.S.-listed diagnostics maker.
Revenue for the three months ended Sept. 27 was $618.9 million, down from the year-earlier period. QuidelOrtho’s 10-Q records China segment revenue at $48.9 million, compared with $84.6 million a year earlier, a 42% decline.
A separate company reconciliation puts China revenue excluding respiratory at $48.4 million, down 42.7% at reported exchange rates and 45.9% on a constant-currency basis. Respiratory revenue fell 38.7% to $68.8 million. Point of Care revenue declined 27.3% to $119.6 million, which QuidelOrtho primarily linked to lower respiratory product revenue and a softer respiratory season.
The China downturn also reflected lower Immunohematology revenue, the company said. QuidelOrtho’s filing says distributor sales in its Labs business slowed after China changed its pricing rules. The China National Health Security Administration (NHSA) issued draft in vitro diagnostics pricing guidelines in March and finalized nationwide guidelines in mid-August, according to the filing. QuidelOrtho said uncertainty about the policy and its rollout contributed to lower customer purchases during the first nine months of 2026.
QuidelOrtho narrowed its 2026 revenue outlook to $2.52 billion to $2.54 billion, from a previous range of $2.52 billion to $2.60 billion. It expects its restructuring program to produce more than $80 million in annual savings in 2027, with $30 million to $35 million in one-time charges in the fourth quarter of 2026.
Levi & Korsinsky’s notice cited an approximately 14% drop in QDEL shares after the results but gave no dates or prices for that calculation. Stock Analysis’ historical data show shares rose 1.85% on Nov. 4, the first session after the company announced results on Nov. 3, then fell 10.52% on Nov. 5 and 16.67% on Nov. 6. The law firm also described China revenue as down 45% without defining the measure; QuidelOrtho’s 45.9% figure applies to China revenue excluding respiratory on a constant-currency basis. The notice announced an investigation and did not identify a filed lawsuit or establish that a securities-law violation occurred.



